Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalba Mansi

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Chimia|July 8, 2021
Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-BedsideRosalba Mansi, Melpomeni Fani
Journal of Labelled Compounds & Radiopharmaceuticals|May 22, 2019
Design and development of the theranostic pair <sup>177</sup> Lu-OPS201/<sup>68</sup> Ga-OPS202 for targeting somatostatin receptor expressing tumorsRosalba Mansi, Melpomeni Fani
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATERosalba Mansi, Pascale Plas, Georges Vauquelin, et al.
Cancers|March 10, 2022
Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of RadiopharmaceuticalsMelpomeni Fani, Rosalba Mansi, Guillaume P Nicolas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Bombesin-Targeted PET of Prostate CancerRosalba Mansi, Ryogo Minamimoto, Helmut Mäcke, et al.
Nature Reviews. Urology|March 20, 2013
Targeting GRPR in urological cancers--from basic research to clinical applicationRosalba Mansi, Achim Fleischmann, Helmut R Mäcke, et al.
EJNMMI Research|November 19, 2013
Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic propertiesSusanne Kossatz, Rosalba Mansi, Martin Béhé, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2023
Peptide Radioligands in Cancer Theranostics: Agonists and AntagonistsBerthold A Nock, Panagiotis Kanellopoulos, Lieke Joosten, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 21, 2004
Criteria for the design and biological characterization of radiolabeled peptide-based pharmaceuticalsEttore Benedetti, Giancarlo Morelli, Antonella Accardo, et al.
Journal of the American Chemical Society|November 2, 2013
Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targetingCarsten Kroll, Rosalba Mansi, Friederike Braun, et al.
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Chimia|July 8, 2021
Radiolabeled Peptides for Cancer Imaging and Therapy: From Bench-to-BedsideRosalba Mansi, Melpomeni Fani
Journal of Labelled Compounds & Radiopharmaceuticals|May 22, 2019
Design and development of the theranostic pair <sup>177</sup> Lu-OPS201/<sup>68</sup> Ga-OPS202 for targeting somatostatin receptor expressing tumorsRosalba Mansi, Melpomeni Fani
Pharmaceuticals (Basel, Switzerland)|December 28, 2021
Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [<sup>177</sup>Lu]Lu-OPS201 Compared to the Agonist [<sup>177</sup>Lu]Lu-DOTA-TATERosalba Mansi, Pascale Plas, Georges Vauquelin, et al.
Cancers|March 10, 2022
Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of RadiopharmaceuticalsMelpomeni Fani, Rosalba Mansi, Guillaume P Nicolas, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 4, 2016
Bombesin-Targeted PET of Prostate CancerRosalba Mansi, Ryogo Minamimoto, Helmut Mäcke, et al.
Nature Reviews. Urology|March 20, 2013
Targeting GRPR in urological cancers--from basic research to clinical applicationRosalba Mansi, Achim Fleischmann, Helmut R Mäcke, et al.
EJNMMI Research|November 19, 2013
Influence of d-glutamine and d-glutamic acid sequences in optical peptide probes targeted against the cholecystokinin-2/gastrin-receptor on binding affinity, specificity and pharmacokinetic propertiesSusanne Kossatz, Rosalba Mansi, Martin Béhé, et al.
Pharmaceuticals (Basel, Switzerland)|May 27, 2023
Peptide Radioligands in Cancer Theranostics: Agonists and AntagonistsBerthold A Nock, Panagiotis Kanellopoulos, Lieke Joosten, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|September 21, 2004
Criteria for the design and biological characterization of radiolabeled peptide-based pharmaceuticalsEttore Benedetti, Giancarlo Morelli, Antonella Accardo, et al.
Journal of the American Chemical Society|November 2, 2013
Hybrid bombesin analogues: combining an agonist and an antagonist in defined distances for optimized tumor targetingCarsten Kroll, Rosalba Mansi, Friederike Braun, et al.
Pageof 6